An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the Anti-CEACAM6 Antibody BAY1834942 in Patients With Advanced Solid Tumors

Trial Profile

An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the Anti-CEACAM6 Antibody BAY1834942 in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2018

At a glance

  • Drugs BAY 1834942 (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 20 Jul 2018 Status changed from planning to recruiting.
    • 11 Apr 2018 New trial record
    • 05 Apr 2018 According to a Bayer media release, company is planning to start this study in 2018. Bayer is developing this drug in collaboration with German Cancer Research Center (DKFZ).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top